Clinical trial · Observational
An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US
An Observational Study of Patients With Philadelphia Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US
NCT02783651CI-TRIAL-00044830completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A retrospective chart review study of Philadelphia chromosome-negative R/R ALL patients in the US.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed/Refractory Acute Lymphoblastic Leukemia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Other | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- No treatment 1
- description
- It is planned to have 20-30 sites participating on the trial for chart review of approximately 200-235 patients initiating treatment for Philadelphia chromosome-negative (Ph-) Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) between January 2013 and March 2019.
- interventionNames
- Other: Other
- label
- No Treatment 2
- description
- Initial record abstraction will occur at study site with subsequent reviews occurring at the site every 3 months thereafter until study conclusion on March 2020.
- interventionNames
- Other: Other
Primary outcomes (3)
- measure
- Treatment patterns in patients with Ph- R/R ALL
- timeFrame
- 86 months
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria -Medical records of patients initiating treatment for Ph- R/R ALL at participating clinical centers in the US between January 2013 and March 2019 will be eligible for inclusion. Exclusion Criteria * Medical records of patients with Ph+ ALL will be excluded. * If informed consent is required, medical records of patients who do not provide informed consent will be excluded.
References
Publications (0)
Data not yet available
No reference posted for this study.